9 research outputs found
Fibroma desmoplásico del hueso: aportación de un nuevo caso
Se presenta un caso de Fibroma Desmoplásico localizado en cuello femoral en
un paciente adulto joven de 34 años, al cual se le practicó una resección amplia de la lesión
y una reconstrucción por medio de un compuesto de aloinjerto intercalar proximal y prótesis
total de cadera (aloprótesis). Un año después de la intervención no hay recidiva local de la
lesión y se objetiva una buena incorporación del aloinjerto al huésped; con buena función de
la cadera. Se revisa la literatura y se discuten algunas consideraciones diagnósticas y terapéuticas
de la lesión.A case of Desmoplastic Fibroma of the Bone, located in the femoral neck, in
a 34 year old male patient is reported. The tumor was treated by wide resection, the reconstruction
beem performed with an allograft-prostheses composite. One year after surgery, there was
no local recurrence and a good is incorporation of the allograft to the host was observed. The
patient showed a good hip function. The literature is reviewed and diagnostic and therapeutic
considerations are discussed
Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer
Background: Activation of the MET oncogene promotes tumor growth, invasion and metastasis in several tumor
types. Additionally, MET is activated as a compensatory pathway in the presence of EGFR blockade, thus resulting in a
mechanism of resistance to EGFR inhibitors.
Methods: We have investigated the impact of HGF and MET expression, MET activation (phosphorylation), MET gene
status, and MET-activating mutations on cetuximab sensitivity in recurrent or metastatic squamous cell carcinoma of
the head and neck (HNSCC) patients.
Results: A single-institution retrospective analysis was performed in 57 patients. MET overexpression was detected in
58 % patients, MET amplification in 39 % and MET activation (p-MET) in 30 %. Amplification was associated with MET
overexpression. Log-rank testing showed significantly worse outcomes in recurrent/metastatic, MET overexpressing
patients for progression-free survival and overall survival. Activation of MET was correlated with worse PFS and OS. In
multivariate logistic regression analysis, p-MET was an independent prognostic factor for PFS. HGF overexpression was
observed in 58 % patients and was associated with MET phosphorylation, suggesting a paracrine activation of the
receptor.
Conclusions: HGF/MET pathway activation correlated with worse outcome in recurrent/metastatic HNSCC patients.
When treated with a cetuximab-based regimen, these patients correlated with worse outcome. This supports a dual
blocking strategy of HGF/MET and EGFR pathways for the treatment of patients with recurrent/metastatic HNSCCThe present
work was supported by grants from the Spanish Ministerio de Economia y
Competitividad (MINECO) (AES Program, grant PI12/01552); the Ministerio de
Sanidad (Cancer Network); the Comunidad de Madrid (S2010/BMD-2344).
The Fundacion Jimenez Diaz Biobank is funded by a grant from the MINECO
(Instituto de Salud Carlos III, RETICS Red de Biobancos, with FEDER funds,
RD09/0076/00101). S.Z. and C.C. are supported by grants from the same
Biobanks initiativ
An imported case of vaccine-derived poliovirus type 2, Spain in the context of the ongoing polio Public Health Emergency of International Concern, September 2021
The monthly retrospective search for unreported acute flaccid paralysis (AFP) cases conducted as a complementary component of the Spanish AFP surveillance system identified a case of AFP in a child admitted in Spain from Senegal during August 2021. Vaccine-derived poliovirus 2 was identified in the stool in September 2021. We present public health implications and response undertaken within the framework of the National Action Plan for Polio Eradication and the Public Health Emergency of International Concern.S
Neurites regrowth of cortical neurons by GSK3b inhibition independently of Nogo Receptor 1
Lesioned axons do not regenerate in the adult mammalian central nervous system, owing to the overexpression of inhibitory molecules such as myelin-derived proteins or chondroitin sulphate proteoglycans. In order to overcome axon inhibition, strategies based on extrinsic and intrinsic treatments have been developed. For myelin-associated inhibition, blockage with NEP1-40, receptor bodies or IN-1 antibodies has been used. In addition, endogenous blockage of cell signalling mechanisms induced by myelin-associated proteins is a potential tool for overcoming axon inhibitory signals. We examined the participation of glycogen synthase kinase 3 (GSK3) and ERK1/2 in axon regeneration failure in lesioned cortical neurons. We also investigated whether pharmacological blockage of GSK3 and ERK1/2 activities facilitates regeneration after myelin-directed inhibition in two models: i) cerebellar granule cells and ii) lesioned entorhino-hippocampal pathway in slice cultures, and whether the regenerative effects are mediated by Nogo Receptor 1 (NgR1). We demonstrate that, in contrast to ERK1/2 inhibition, the pharmacological treatment of GSK3 inhibition strongly facilitated regrowth of cerebellar granule neurons over myelin independently of NgR1. Lastly these regenerative effects were corroborated in the lesioned EHP in NgR1 -/- mutant mice. These results provide new findings for the development of new assays and strategies to enhance axon regeneration in injured cortical connections
Additional file 1: of Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer
Figure S1. Representative qRT-PCR analysis for EGFR and HGF mRNA copy levels. A. Standard curves for target EGFR, HGF and reference probe ATP5E, as determined by 5 or 8 triplicate points over a range from 0.05 to 10 ng. The efficiencies (E) were calculated from the slope of the standard curves according to the equation: E = (10[-1/slope]-1), by using 5 or 8 dilution points. The efficiencies were determined as follows: EEGFR= 1.974; EHGF= 2.091; EATP5E= 1.902. RFU, relative fluorescence units. B. qPCR amplification curves of EGFR, HGF and ATP5E probes, in triplicate, for a representative sample, showing the distance with the calibrator sample
PrP(106-126) activates neuronal intracellular kinases and Egr1 synthesis through activation of NADPH-oxidase independently of PrPc.
Prion diseases are characterised by severe neural lesions linked to the presence of an abnormal protease-resistant isoform of cellular prion protein (PrPc). The peptide PrP(106-126) is widely used as a model of neurotoxicity in prion diseases. Here, we examine in detail the intracellular signalling cascades induced by PrP(106-126) in cortical neurons and the participation of PrPc. We show that PrP(106-126) induces the activation of subsets of intracellular kinases (e.g., ERK1/2), early growth response 1 synthesis and induces caspase-3 activity, all of which are mediated by nicotinamide adenine dinucleotide phosphate hydrogen-oxidase activity and oxidative stress. However, cells lacking PrPc are similarly affected after peptide exposure, and this questions the involvement of PrPc in these effects
Elaboración de guías de práctica clínica en el Sistema Nacional de Salud. Actualización del manual metodológico
Actualización del manual para la realización de guías de práctica clínica para el Sistema Nacional de Salud, dentro del programa de Guiasalud